Literature DB >> 25371372

Intrahepatic cholestasis of pregnancy and timing of delivery.

Jamie O Lo1, Brian L Shaffer1, Allison J Allen1, Sarah E Little2, Yvonne W Cheng3, Aaron B Caughey1.   

Abstract

OBJECTIVE: We examined the morbidities from delivery at earlier gestational ages versus intrauterine fetal demise (IUFD) for women with intrahepatic cholestasis of pregnancy (ICP) to determine the optimal gestational age for delivery.
METHODS: A decision-analytic model was created to compare delivery at 35 through 38 weeks gestation for different delivery strategies: (1) empiric steroids; (2) steroids if fetal lung maturity (FLM) negative; (3) wait a week and retest if FLM negative; or (4) deliver immediately. Literature review identified 18 studies that estimated IUFD in ICP; we used the mean rate, 1.74%, and assumed a uniform distribution from 34 to 40 weeks gestation. Large cohort data was used to calculate neonatal morbidity rates at each gestational age. Maternal and neonatal quality-adjusted life years (QALYs) were combined. Univariate sensitivity and Monte Carlo analyses were performed to test for robustness.
RESULTS: Immediate delivery at 36 weeks without FLM testing and steroid administration was the optimal strategy as compared to delivery at 36 weeks with steroids (+47 QALYs) and as compared to immediate delivery at 35 weeks (+210 QALYs). Our results were robust up to a 30% increase in the rate of IUFD.
CONCLUSION: Immediate delivery at 36 weeks in women with ICP is the optimal delivery strategy.

Entities:  

Keywords:  Cholestasis; decision analytic model; gestational age; intrahepatic cholestasis; late preterm delivery; pregnancy

Mesh:

Year:  2014        PMID: 25371372     DOI: 10.3109/14767058.2014.984605

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  12 in total

Review 1.  Review of a challenging clinical issue: Intrahepatic cholestasis of pregnancy.

Authors:  Sebiha Ozkan; Yasin Ceylan; Orhan Veli Ozkan; Sule Yildirim
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

2.  Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy.

Authors:  Tetsuya Kawakita; Laura I Parikh; Patrick S Ramsey; Chun-Chih Huang; Alexander Zeymo; Miguel Fernandez; Samuel Smith; Sara N Iqbal
Journal:  Am J Obstet Gynecol       Date:  2015-06-10       Impact factor: 8.661

3.  Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy.

Authors:  Cristina Manzotti; Giovanni Casazza; Tea Stimac; Dimitrinka Nikolova; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2019-07-05

4.  Drug resistant fetal arrhythmia in obstetric cholestasis.

Authors:  Nahide Altug; Ayse Kirbas; Korkut Daglar; Ebru Biberoglu; Dilek Uygur; Nuri Danisman
Journal:  Case Rep Obstet Gynecol       Date:  2015-03-03

5.  Effect of Intrahepatic Cholestasis of Pregnancy on Neonatal Birth Weight: A Meta-Analysis.

Authors:  Li Li; Yuan Hua Chen; Yuan Yuan Yang; Lin Cong
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-08-21

6.  Perinatal outcomes in intrahepatic cholestasis of pregnancy with monochorionic diamniotic twin pregnancy.

Authors:  Youwen Mei; Yonghong Lin; Dan Luo; Lan Gao; Li He
Journal:  BMC Pregnancy Childbirth       Date:  2018-07-06       Impact factor: 3.007

7.  Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses.

Authors:  Caroline Ovadia; Paul T Seed; Alexandros Sklavounos; Victoria Geenes; Chiara Di Ilio; Jenny Chambers; Katherine Kohari; Yannick Bacq; Nuray Bozkurt; Romana Brun-Furrer; Laura Bull; Maria C Estiú; Monika Grymowicz; Berrin Gunaydin; William M Hague; Christian Haslinger; Yayi Hu; Tetsuya Kawakita; Ayse G Kebapcilar; Levent Kebapcilar; Jūratė Kondrackienė; Maria P H Koster; Aneta Kowalska-Kańka; Limas Kupčinskas; Richard H Lee; Anna Locatelli; Rocio I R Macias; Hanns-Ulrich Marschall; Martijn A Oudijk; Yael Raz; Eli Rimon; Dan Shan; Yong Shao; Rachel Tribe; Valeria Tripodi; Cigdem Yayla Abide; Ilter Yenidede; Jim G Thornton; Lucy C Chappell; Catherine Williamson
Journal:  Lancet       Date:  2019-02-14       Impact factor: 202.731

8.  Women successfully treated for severe intrahepatic cholestasis of pregnancy do not have increased risks for adverse perinatal outcomes.

Authors:  Jielian Yang; Chong Chen; Min Liu; Shuye Zhang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

9.  Relationship between early onset severe intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid.

Authors:  Maria C Estiú; Maria A Frailuna; Carla Otero; Marcela Dericco; Catherine Williamson; Jose J G Marin; Rocio I R Macias
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240

10.  Outpatient versus inpatient follow-up for intrahepatic cholestasis of pregnancy.

Authors:  Ozgur Ozyuncu; Gokcen Orgul; Gonca Ozten; Murat Yurdakok; Mehmet Sinan Beksac
Journal:  Clin Exp Hepatol       Date:  2019-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.